Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction

Trial Profile

Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2017

At a glance

  • Drugs AAV2hAQP1 (Primary)
  • Indications Head and neck cancer; Squamous cell cancer; Xerostomia
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 21 Jun 2016 Planned End Date changed from 1 Feb 2022 to 1 Nov 2022.
    • 21 Jun 2016 Planned primary completion date changed from 1 Feb 2022 to 1 Nov 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top